Tailoring Immunotherapy Strategies for Advanced NSCLC

EP: 1.Expert Insights on Recent Advancements in LS-SCLC

EP: 2.Key Updates in the Treatment of ES-SCLC

EP: 3.Expert Perspectives on Tarlatamab in ES-SCLC

EP: 4.Looking Ahead in SCLC: ADCs and Other Novel Agents

EP: 5.Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapy in Early-Stage NSCLC

EP: 7.New Targeted Approaches in Unresectable Early-Stage NSCL

EP: 8.Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP: 9.Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP: 10.Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations

EP: 11.Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

Now Viewing

EP: 12.Tailoring Immunotherapy Strategies for Advanced NSCLC

Video content above is prompted by the following:

• How do you select between mono immunotherapy (IO) and dual IO therapy in patients with advanced NSCLC and no actionable mutations?
• In which patients do you consider the addition of chemotherapy?
• How does PD-L1 status influence your decision?
• What is your preferred management strategy for patients with SQ histology? STK11 or KEAP1? What data influence your treatment approach?
• What advancements in lung cancer from 2024 will have the most significant impact on your clinical practice in 2025?
• What do you see as the greatest treatment gaps and unmet needs in the management of advanced NSCLC, and what are the most promising opportunities for future advancements?